Renaissance Technologies
CDIO icon

Renaissance Technologies’s Cardio Diagnostics CDIO Stock Holding History

Renaissance Technologies’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
49,200
+33,852
+221% +$64K ﹤0.01% 2971
2026
Q1 		$29.9K Buy
+15,348
New +$40.2K ﹤0.01% 3145
2023
Q4 		– Sell
-593
Closed -$6K – 3772
2023
Q3 		$6K Buy
+593
New +$14.3K ﹤0.01% 3598

Other funds holding CDIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's CDIO Position: Q2 2026 in Review

Renaissance Technologies increased its Cardio Diagnostics (CDIO) stake by 221% in Q2 2026, buying an estimated $64K and bringing the position to 49,200 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

Renaissance Technologies first reported a position in CDIO in Q3 2023 and has held it in 3 quarters since. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Renaissance Technologies held 49,200 shares of Cardio Diagnostics worth $108K as of Q2 2026.
  • Renaissance Technologies bought 33,852 Cardio Diagnostics shares in Q2 2026, an estimated $64K.
  • Cardio Diagnostics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2971 holding.
  • Renaissance Technologies first reported a position in Cardio Diagnostics in Q3 2023 and has held it in 3 quarters since.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.